191 results about "Hepatoma cell" patented technology

The invention relates to the field of natural products, in particular to a dimer compound of guaiane type sesquiterpenes and uric acid as well as an extraction and separation method and application of the dimer compound. According to the invention, a new dimer compound of guaiane type sesquiterpene and uric acid is extracted and separated from carpesium abrotanoides in Guizhou, and it is found that the dimer compound has relatively strong anti-tumor activity. The compound has strong inhibitory activity on breast cancer, prostate cancer, nasopharynx cancer, liver cancer, lung cancer, leukemia, pancreatic cancer, glioma, osteosarcoma, skin cancer, cervical cancer, ovarian cancer, kidney cancer and esophageal cancer, and provides an optional scheme for broad-spectrum anti-cancer drugs. Moreover, in human prostate cancer cells PC3, human cervical cancer cells Hela, human liver cancer cells HepG2 and human glioma cells U87 which are resistant to paclitaxel, the compound also shows strong anti-cancer activity, which indicates that the compound has the potential of treating patients resistant to paclitaxel.

The invention relates to the technical field of medical instruments, and provides a steep pulse-based ablation system and method for liver cancer cells, and the system comprises a tumor feature recognition module which is used for obtaining imaging images of the liver cancer cells and recognizing tumor features, blood supply conditions and tumor centers of the liver cancer cells; the electrode inlet setting module is used for setting a safety boundary of liver cancer cells and setting an ablation area and a focus skin surface of the liver cancer cells based on the safety boundary and tumor characteristics; the ablation effect analysis module is used for calculating the electrode depth and the electrode angle of the liver cancer cells and analyzing the coverage effect of an ablation area; the electric field intensity identification module is used for analyzing cell membrane characteristics of the hepatoma cells, identifying the electroporation effect of the hepatoma cells and identifying the electric field intensity of the hepatoma cells; and the steep pulse ablation module is used for performing ablation treatment on the liver cancer cells in combination with the electric field intensity and a pulse generator to obtain an ablation result. The invention aims to avoid heat injury of surrounding tissues and improve the ablation effect of liver cancer cells.

The invention relates to a gadolinium-doped carbon dot complex based on liver cancer cell membrane coating and a preparation method of the gadolinium-doped carbon dot complex. The gadolinium-doped carbon dot complex is prepared on the basis of gadolinium-doped carbon dots Gd-CDs which are prepared from indocyanine green, citric acid, polyethylene glycol and gadolinic acid through a one-step microwave thermal method and have fluorescence-magnetic resonance bimodal imaging capacity. The Gd-CDs complex Gd-CDs coated HCM is placed in a cell membrane suspension extracted from human hepatoma carcinoma cells HepG2, and the Gd-CDs complex Gd-CDs coated HCM which is uniform in particle size and has the capacity of photothermal and immunotherapy of hepatocellular carcinoma is obtained through extrusion construction of a liposome extruder. The Gd-CDs (at) HCM complex constructed by the invention not only has good bimodal imaging ability, but also has a specific inhibition effect on liver tumor cells, can be applied to preparation of drugs for inhibiting the growth of the liver tumor cells, and realizes a good treatment effect on liver cancer at a nanometer level.

The invention relates to the technical field of nano-drug presentation systems, in particular to a nanoparticle for synergistically promoting hepatoma ferroptosis based on mesoporous manganese dioxide, salazosulfapyridine and a tumor cell biological membrane as well as a preparation method and application of the nanoparticle. The nanoparticle in the scheme comprises mesoporous manganese dioxide which is modified with a tumor cell membrane on the surface and loaded with salazosulfapyridine. According to the technical scheme, the nanoparticles can effectively induce hepatoma cell ferroptosis through a multi-target strategy. The salazosulfapyridine and the mesoporous manganese dioxide have a synergistic effect to enhance the ferroptosis effect; the tumor cell biological membrane has homologous targeting property, so that the accumulation capacity of the nanoparticles in liver cancer tissues is remarkably improved; the nanoparticle provided by the invention not only can be used for treatment, but also can monitor the change in the treatment process in real time. According to the technical scheme, the technical problem that a nano-drug presentation system for effectively inducing ferroptosis aiming at multiple target spots is lacked in the prior art can be solved, and the technical scheme has important significance in improving the survival rate and the life quality of liver cancer patients.

The invention belongs to the field of microorganisms, and particularly relates to a pleurotus citrinopileatus strain for producing ergothioneine and a preparation method and application of ergothioneine. The pleurotus citrinopileatus strain is preserved in China General Microbiological Culture Collection Center (CGMCC). According to the preparation method of the ergothioneine, lactose and casein peptone are used as a carbon source and a nitrogen source of a liquid fermentation culture medium. The pleurotus citrinopileatus strain is used for high yield of ergothioneine, and the ergothioneine produced by fermentation is used for relieving oxidative stress damage of hepatoma carcinoma cells HepG2.

The invention relates to preparation of 10-trifluoromethoxy camptothecin compounds and application of the 10-trifluoromethoxy camptothecin compounds in antitumor drugs. The structural formula of the compounds is shown in the specification. In-vitro cytotoxic activity screening results show that the 10-trifluoromethoxy camptothecin compound has broad-spectrum anti-tumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1) and human pancreatic cancer cells (BxPC-3). The compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II have a relatively strong inhibition effect on the detected seven tumor cell lines, and the IC50 (half maximal inhibitory concentration) values of the compound 10-trifluoromethoxy camptothecin I and the compound 7-ethyl-10-trifluoromethoxy camptothecin II are respectively 0.913 to 0.0661 mu M and 4.932 to 0.0578 mu M, which are obviously superior to those of a contrast drug topotecan. Wherein the compound I and the compound II show the strongest inhibitory activity on a BxPC-3 cell line, and the IC50 values of the compound I and the compound II are 0.0661 + / -0.0065 [mu] M and 0.0578 + / -0.0043 [mu] M respectively. Therefore, the 10-trifluoromethoxy camptothecin compound is expected to be developed into a novel antitumor drug. # imgabs0 #

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention relates to the field of biological medicine manufacturing, in particular to a preparation method and application of nanoparticles for destroying hepatoma cell ferritin, and provides ultrasonic response type nanoparticles (NPs) composed of polylactic acid-glycolic acid (PLGA) modified by ferritin homing peptide (HKN15) and acoustic droplet vaporization (ADV) material perfluorohexane (PFH). Through the positive feedback effect of overexpression of the HKN15 and the tumor cell ferritin, the NPs (HKN15-coated PLGA-PFH) specifically gathers around the ferritin in the HCC cell. Tumor cells can be directly killed by a cavitation effect generated by ADV through ultrasonic irradiation of a tumor area; more importantly, along with collapse of ferritin, the concentration of iron in cells is increased, so that inevitable ferroptosis is caused. The scheme can destroy hepatoma cell ferritin, increase the concentration of free iron in the hepatoma cell ferritin and induce a ferroptosis effect to achieve the purpose of tumor treatment.

The invention belongs to the technical field of cancer resistance, and relates to a preparation method and application of curcumin-loaded composite nanoparticles. Sodium alginate and carboxymethyl chitosan chelated metal calcium ions are synthesized by adopting a liquid phase precipitation method to form double-skeleton packaged curcumin and manganese carbonate doped CuratCMCS / SA-CaCO3 / MnCO3 nanoparticles, the characteristics of poor water solubility and low bioavailability of curcumin are overcome, the drug loading rate is improved, a compact calcium shell structure also has acid responsiveness, and the drug loading capacity is improved. And the drug can be specifically disintegrated and released in an acidic tumor microenvironment. The nanoparticles show remarkable cytotoxicity to human hepatoma carcinoma cells HepG2, have a remarkable inhibition effect and can effectively induce cell apoptosis.

The invention provides a preparation method of a hybrid cell membrane modified nano-drug for inhibiting interment of macrophages. According to the invention, a multifunctional bionic nano-drug with a'core-shell 'structure is prepared from liver cancer cell membrane and bone marrow-derived macrophage membrane hybrid double-drug-loading carrier nanoparticles. In the application, the bionic function of macrophages is firstly realized, so that the drug is prevented from being swallowed by mononuclear macrophages in vivo, and the side effect of the drug is reduced; secondly, by utilizing the homologous targeting effect of hepatoma carcinoma cells of Hepa1-6, the aggregation of the medicine in tumors is enhanced, and the utilization efficiency of the medicine is improved; finally, the two drugs including sorafenib and Xkr8siRNA are co-delivered, so that the pharmacokinetics is simplified, and the immunotherapy effect of the liver cancer can be promoted by utilizing the inhibition of the Xkr8siRNA on the intercellular effect.

The invention discloses a capsaicin compound and a preparation method and application thereof, the molecular formula of capsaicin Capsivaryine is C16H21NO3, the chemical structure of capsaicin Capsivaryine is as follows, and the capsaicin Capsivaryine compound is a new compound reported for the first time and is prepared by taking mature and dry fruits of capsicum as raw materials through crushing, sieving, silica gel column treatment, D101 macroporous resin treatment and HPLC (High Performance Liquid Chromatography). The compound disclosed by the invention has a certain in-vitro inhibition effect on human breast cancer cells MCF-7, human liver cancer cells HEPG2, human non-small cell lung cancer cells A549 and human ovarian cancer cells SKOV3, and has no toxicity on human normal liver cells L02. The compound is a natural product which is novel in structure and good in activity, has great potential in the anti-tumor aspect, enriches diversity of pepper plants, and provides guidance for research of chemical components of pepper. # imgabs0 #

The application discloses antitumor application of a fluorine-containing indole compound. The fluorine-containing indole compound has the following structure, wherein R1, R2 and R3 are independently halogen, -CN, -NO2, C 1‑6 alkyl, C 1‑6 alkoxy, C 1‑6 haloalkyl, C 1‑6 acyl. The compound has significant cytotoxic activity on human tumor cells selected from any one or more of human leukemia HL-60 cells, human lung cancer A549 cells, human hepatoma SMMC-7721 cells, human breast cancer MDA-MB-231 cells and human colon cancer SW480 cells.

The invention relates to a tumor hypoxia specific response BODIPY fluorescent probe as well as preparation and application thereof. The invention relates to a BODIPY fluorescent probe which is synthesized by utilizing tumor hypoxia to respond to azobenzene groups. The probe has no signal to normal oxygen cells, shows strong near-infrared fluorescence to hypoxia cancer cells, and can be used for visually detecting deep solid tumors. According to the present invention, the tumor specific response BODIPY fluorescent probe is adopted as the research object, the human liver cancer cells (HepG2) and the human non-small cell lung cancer cells (A549) are adopted as the tested cell strains, the fluorescence detection ability research under the normal oxygen and oxygen deficiency conditions is developed, and the foundation is established for the real-time accurate tumor detection. The fluorescent probe has the advantages of lower preparation cost, simpler synthesis method, easily available raw materials, less side reaction, high yield, easiness in purification, easiness in industrial production and the like.

The invention discloses a construction method of a large-scale liver cancer model co-cultured with immune cells, and relates to the technical field of liver cancer model construction. The method comprises the following steps: preparing primary hepatoma cells from in-vitro hepatoma tumor tissues, mixing the primary hepatoma cells with supporting hydrogel, refrigerating, and printing in a 12-pore plate to obtain a hepatoma printing body; placing the liver cancer printing body in a 100mM calcium chloride solution to quickly crosslink the liver cancer printing body, then culturing the liver cancer printing body by using a DMEM + 10% FBS culture medium, replacing a fresh culture medium every 2 days, and culturing for 5 days to obtain a large-scale liver cancer model; the CD8 + T cells and the large-scale liver cancer model are co-cultured for 48 h according to different proportions of 1: 1, 2: 1 and 5: 1, and the large-scale liver cancer model co-cultured with immune cells is obtained. The liver cancer model has the advantages of being uniform in size, stable in character, high in throughput and capable of easily reflecting cell activity. The model can reflect the effects of immunotherapy drugs such as PD1 and the like.

The invention discloses novel application of ganoderic acid B, belongs to the field of liver injury treatment, and particularly relates to application of ganoderic acid B in preparation of a medicine for treating liver cell injury caused by aflatoxin. According to the invention, human liver cancer HepG2 cells are utilized to construct an AFB1 cell injury model, lucid ganoderma active ingredients with a protection effect on injury are screened out, and the resistance mechanism of the lucid ganoderma active ingredients is researched and predicted, so that a new method and a new target spot are provided for searching for diseases caused by AFB1 prevention and treatment. A new method can be provided for preventing and treating the liver cancer caused by the AFB1.

The invention discloses application of chidamide in preparation of an anti-hepatoma drug synergist, and belongs to the technical field of medicines. According to the preparation for effectively improving the treatment effect of the anti-hepatoma medicine, chidamide serves as a sensitizer of the anti-tumor medicine, uptake of the anti-hepatoma medicine by hepatoma cells is promoted by up-regulating OATP1B3 protein expression in hepatoma tissue, accumulation of the medicine in the hepatoma tissue is increased, and therefore the anti-tumor effect of the medicine is improved. Combination of chidamide and the anti-liver cancer drug can synergistically enhance the toxicity of the drug to liver cancer, and the drug combination has biological safety and has great clinical application prospects.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-GPC3 monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The high-affinity anti-GPC3 sequence is obtained through screening, the binding specificity of the high-affinity anti-GPC3 sequence and the GPC3 antigen is high, and dissociation is slow. The sequence is used as an extracellular targeting domain to construct GPC3-CAR, after macrophages are transduced through lentivirus, CAR-M can specifically recognize GPC3 positive target cells, activate intracellular signal channels and remarkably improve in-vitro phagocytosis and killing activity, the hepatoma cell lysis effect is better, and technical support is provided for anti-hepatoma application.

The invention discloses a 1, 8-disubstituted tryptanthrin derivative and application of the 1, 8-disubstituted tryptanthrin derivative to prevention and treatment of phytopathogen and anti-tumor activity, the general formula of the derivative is shown in (I), and the test result of the compound shown in the general formula on the bacterial activity of phytopathogen shows that the compound has a good antibacterial effect on Xanthomonas oryzae pv. Oryzae, Xanthomonas citri pv. Citri and the like, and can be used for preventing and treating the phytopathogen. The method can be used for developing novel agricultural bactericides. Meanwhile, results of the compound shown in the general formula on tumor cells show that the compound has good in-vitro anti-tumor activity on human chronic myelogenous leukemia cells K562, human lung cancer cell lines A549, human liver cancer cells HepG2, human prostate cancer cells PC3 and the like, and can be used for researching novel anti-tumor drugs. # imgabs0 #

The invention relates to preparation of trifluoromethyl camptothecin compounds and application of the trifluoromethyl camptothecin compounds in antitumor drugs. The structural formula of the compounds is shown in the specification. In-vitro cytotoxic activity screening results show that the trifluoromethyl camptothecin compound has broad-spectrum anti-tumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human bile duct cancer cells (QBC939), human breast cancer cells (MCF-7), human pancreatic cancer cells (PANC-1) and human pancreatic cancer cells (BxPC-3). The four trifluoromethyl camptothecin compounds I, II, III and IV show a relatively strong inhibition effect on the seven detected tumor cell lines, and the IC50 values of the four trifluoromethyl camptothecin compounds I, II, III and IV are respectively 0.503 to 0.0112 [mu] M, 4.8477 to 0.6516 [mu] M, 1.825 to 0.0005 [mu] M and 4.9043 to 0.4612 [mu] M, which are obviously superior to those of a control drug topotecan. Wherein the compound shows the strongest inhibitory activity on a BxPC-3 cell line, and the IC50 (half maximal inhibitory concentration) value is in a range of 0.6516 to 0.0005 mu M. Therefore, the trifluoromethyl camptothecin compound is expected to be developed into a novel antitumor drug. # imgabs0 #

The present invention relates to the technical field of anti-tumor compounds, and discloses an anti-tumor active compound, an extraction and separation method, a drug and uses thereof. The compound has a chemical structure of formula I, or a pharmaceutical composition of a pharmaceutically acceptable salt, stereoisomer, hydrate, solvate or prodrug of the compound of formula I. The present invention can extract and prepare an anti-tumor active compound from Leucosceptrum canum, and this compound has an inhibitory effect on human liver cancer cells.

The invention discloses application of sodium cantharidinate in preparation of a medicine for promoting CD3 + T cell proliferation, sodium cantharidinate acts on CD3 + T cells, proliferation of the CD3 + T cells can be promoted, human immunity can be effectively improved, and human lung cancer cells H460, human lung cancer cells A549 and human liver cancer cells HepG2 can be effectively killed.

The application relates to a synthesis method of red luminescent carbon dots with a targeting diagnosis and treatment potential of hepatocellular carcinoma, which comprises the following steps: 1) adding 5-fluorouracil and indocyanine green into deionized water, uniformly mixing, and forming a uniform mixed solution; 2) heating the mixed solution obtained in the step 1) at 160-200 DEG C for 5-9 h, and cooling to room temperature; 3) filtering and dialyzing the solution obtained in the step 2), and obtaining a pure 5-FICD solution; and 4) freeze-drying the solution obtained in the step 3), and obtaining the product. The method takes anticancer drug 5-fluorouracil and photosensitizer indocyanine green as precursors, synthesizes a low-toxicity red light carbon dot through a simple hydrothermal method, improves the shortcoming that a chemotherapy drug has a large side effect, and realizes the targeted killing of hepatocellular carcinoma cells.

The invention relates to the technical field of fungus active ingredient extraction and medical application, and particularly provides a preparation method and application of phellinus igniarius phenol A. The preparation method comprises the following steps: extracting phellinus igniarius with an ethanol water solution and ethyl acetate in sequence to obtain an extract; the extract is subjected to silica gel column chromatography, Sephadex LH-20 (MeOH) column chromatography and ODS semi-preparative column separation in sequence, and the phellinus igniarius phenol A is obtained. In-vivo animal experiments prove that the phellinus igniarius phenol A has certain in-vitro inhibitory activity on six tumor cells, namely NCI-H460, MKN-45, 22Rv1, MCF7, SiHa and Hep 3B2.1-7, and particularly has the most remarkable in-vitro inhibitory effect on liver cancer Hep3B2.1-7 cells.

This invention belongs to the field of biotechnology and pharmaceutical technology, and discloses an ACLY-targeting PROTAC chimera with anti-MASH activity using a glycol chain as the linking chain. Its general structural formula is Formula 1: R is -(CH2-O-CH2). n -, n is 2-6. The PROTAC compound synthesized in this invention is a novel compound. In a high-fat model established using L02 and HepG2 cells, the synthesized PROTAC compound exhibits activity in reducing TG content. Compared with the warhead, the synthesized PROTAC compound shows low toxicity activity in human hepatocellular carcinoma cells HepG2, normal human hepatocytes L02, and human umbilical vein endothelial cells HUVEC, making it a novel, low-toxicity, and highly effective drug for treating non-alcoholic steatohepatitis (NAH). This invention expands the application areas of PROTAC technology while developing a highly effective treatment for NHA.

The application belongs to the technical field of biology and medicine, and discloses a PROTAC compound with a carbon chain as a connecting chain, which is developed based on a PROTAC technology, and a structural general formula of the PROTAC compound is formula 1: wherein R is -(CH2) n -, and n is 3-8. The synthesized PROTAC compound is a new compound, has a TG content reducing activity in a high-fat model established by L02 and HepG2, and has a low-toxicity activity in human hepatoma cells HepG2, human normal liver cells L02 and human umbilical vein endothelial cells HUVEC compared with a warhead. The synthesized PROTAC compound is a new type of anti-non-alcoholic fatty liver disease drug with low toxicity and high efficiency. The application of the PROTAC technology is widened while developing an efficient treatment of anti-non-alcoholic fatty liver disease.

The present invention discloses a compound with structural formula I. The compound of the present invention exhibits strong inhibitory activity against Mycobacterium tuberculosis, has good antituberculosis effects, and has a significantly reduced MIC value compared with isoniazid, a first-line clinical drug. It has weak inhibitory effects on the proliferation of human hepatoma cells HepG2 and Chang cells and has good safety. In addition, in the experiment of Mycobacterium tuberculosis infection overexpressing DprE1, the antibacterial ability of the compound decreased, further verifying that the compound exerts its antibacterial effect by inhibiting the DprE1 enzyme, and it is a novel DprE1 inhibitor.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The application belongs to the technical field of biological medicine, and particularly relates to a galactosamine-doxetaxel conjugate as well as a preparation method and application thereof. First, doxetaxel and 3,3'-diseleno-dipropionic acid are used as raw materials, and after heating reaction, 3,3'-diseleno-dipropionic acid doxetaxel is obtained. Then, the obtained 3,3'-diseleno-dipropionic acid doxetaxel and galactosamine are used as raw materials, and after heating reaction, galactosamine-3,3'-diseleno-dipropionic acid doxetaxel conjugate is obtained through column chromatography separation and purification. The obtained conjugate can be specifically recognized by endogenous lectin receptors (such as asialoglycoprotein receptor ASGPR) which are highly expressed on the surface of hepatoma cells, so as to be taken up by hepatoma cells through a receptor-mediated pathway, and has application prospect in the direction of hepatoma targeted treatment.

The invention discloses a cynanchum atratum extract as well as a preparation method and application thereof. The cynanchum atratum extract is an extract obtained by extracting cynanchum atratum with 50-80% ethanol. The cynanchum atratum is a root and a rhizome of a Tylophora yunnanensis Schlechter, which is a plant of the Schlechter family, and the root and the rhizome of the Tylophora yunnanensis Schlechter. Cell experiments and animal experiments prove that the extract obtained by extracting cynanchum atratum with 75% ethanol has the effects of inhibiting breast cancer and hepatoma carcinoma cell proliferation, inducing breast cancer and hepatoma carcinoma cell death and reducing tumor volume and tumor quality, has a remarkable effect on treating liver cancer and breast cancer, and has a practical application value.

The invention belongs to the field of biological medicine, and particularly relates to siRNA for inhibiting INHBE gene expression and a conjugate and application thereof. According to the present invention, the corresponding siRNA is designed according to the INHBE gene, and the siRNA is delivered to the liver by coupling GalNAc so as to interfere the INHBE mRNA at the liver position, such that the expression of the INHBE protein can be effectively reduced, the healthy fat storage can be promoted, and the obesity treatment effect can be further achieved. The siRNA and the siRNA conjugate provided by the invention can be used for remarkably inhibiting proliferation of human liver cancer cells Hep-G2, and have an effect on inhibiting mouse liver INHBE mRNA, so that the siRNA and the siRNA conjugate provided by the invention have a good prospect in application of obesity.